Home/Filings/4/0001193125-26-021122
4//SEC Filing

Miller Deborah Ann 4

Accession 0001193125-26-021122

CIK 0001861560other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 4:31 PM ET

Size

14.0 KB

Accession

0001193125-26-021122

Research Summary

AI-generated summary of this filing

Updated

Nuvalent (NUVL) CLO Deborah Miller Exercises Options, Sells Shares

What Happened
Deborah Ann Miller, Chief Legal Officer of Nuvalent, exercised stock options to acquire 15,000 shares (700 on Jan 21; 14,300 on Jan 22) at a strike price of $27.85, paying about $417,750 in aggregate. She then sold the same 15,000 shares in open-market transactions for weighted-average prices of $109.84–$110.16, generating gross proceeds of approximately $1,652,176. The filings also record derivative conversion entries at $0.00 reflecting the option-to-share conversion associated with the exercises.

Key Details

  • Dates: Jan 21, 2026 (700 shares) and Jan 22, 2026 (14,300 shares).
  • Exercise cost: 15,000 shares × $27.85 = $417,750 total (700 → $19,495; 14,300 → $398,255).
  • Sales proceeds: 700 shares @ weighted avg $109.84 = $76,888; 14,300 shares @ weighted avg $110.16 = $1,575,288; total ≈ $1,652,176. Net proceeds before fees/taxes ≈ $1,234,426.
  • Sales were reported with weighted-average prices; reported price ranges: $109.80–$109.90 (smaller lot) and $109.80–$110.75 (larger lot). The filer offers to provide breakdowns by price on request (F2, F3).
  • Transactions were executed pursuant to a Rule 10b5-1 trading plan adopted Nov 18, 2024 (F1).
  • Vesting note: underlying option shares vest monthly over four years beginning Jan 6, 2023 (F4).
  • The Form 4 was filed on Jan 23, 2026 for trades on Jan 21–22; no late filing is indicated.
  • Shares owned after the transactions are not specified in the provided filing excerpt.

Context
This was an option exercise followed by immediate open-market sales of the same shares (a sell-to-cover/cashless-style outcome). Such transactions commonly reflect routine option exercise and planned selling under a pre-established 10b5-1 plan; they are factual disclosures of insider activity and do not by themselves indicate the insider’s outlook on the company.

Insider Transaction Report

Form 4
Period: 2026-01-21
Miller Deborah Ann
Chief Legal Officer
Transactions
  • Exercise/Conversion

    Class A Common Stock

    [F1]
    2026-01-21$27.85/sh+700$19,49560,334 total
  • Sale

    Class A Common Stock

    [F1][F2]
    2026-01-21$109.84/sh700$76,88859,634 total
  • Exercise/Conversion

    Class A Common Stock

    [F1]
    2026-01-22$27.85/sh+14,300$398,25573,934 total
  • Sale

    Class A Common Stock

    [F1][F3]
    2026-01-22$110.16/sh14,300$1,575,28859,634 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F4]
    2026-01-2170089,454 total
    Exercise: $27.85Exp: 2033-01-06Class A Common Stock (700 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F4]
    2026-01-2214,30075,154 total
    Exercise: $27.85Exp: 2033-01-06Class A Common Stock (14,300 underlying)
Footnotes (4)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.80 to $109.90, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
  • [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.80 to $110.75, inclusive.
  • [F4]The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
Signature
/s/ Nathan McConarty, attorney-in-fact|2026-01-23

Documents

1 file

Issuer

Nuvalent, Inc.

CIK 0001861560

Entity typeother

Related Parties

1
  • filerCIK 0001868741

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 4:31 PM ET
Size
14.0 KB